PML body meets telomere
The beginning of an ALTernate ending?

Inn Chung, Sarah Osterwald, Katharina I. Deeg and Karsten Rippe*

Research Group Genome Organization & Function, Deutsches Krebsforschungszentrum (DKFZ) and BioQuant, Heidelberg, Germany

Keywords: alternative lengthening of telomeres, ALT, promyelocytic leukemia nuclear bodies, ALT-associated PML bodies, DNA repair, DNA recombination, cellular immortalization

Abbreviations: ALT, alternative lengthening of telomeres; APB, ALT-associated PML-NB; ATRX, X-linked helicase II; BLM, Bloom syndrome protein; DAXX, death-associated protein 6; DDR, DNA damage response; ECTRs, extrachromosomal telomeric repeats; FISH, fluorescence in situ hybridization; FRAP, fluorescence recovery after photobleaching; GFP, green fluorescence protein; γH2AX, histone variant H2AX with phosphorylated serine 139; HP1, heterochromatin protein 1; LacI, Lac repressor; lacO, lac operator sequence; MMS21, methyl methanesulfonate sensitivity protein 21; NBS1, nijmegen breakage syndrome protein 1; PML, promyelocytic leukemia; PML-NB, PML nuclear body; PNA, peptide nucleic acid; POT1, protection of telomeres 1; Rad, radiation homolog; RAP1, repressor/activator protein 1; SIM, SUMO interacting motif; SMC, structural maintenance of chromosome complex; SUMO, small ubiquitin-related modifier; t-loop, telomeric loop; T-SCE, telomere sister chromatid exchange; TMM, telomere maintenance mechanism; TRF, telomere repeat binding factor; UBC9, ubiquitin carrier protein 9

Due to the end-replication problem and exonucleolytic activities, the ends of linear chromosomes shorten with every cell division. Upon reaching a critical telomere length, DDR factors induce replicative senescence or apoptosis. According to this, the number of cell divisions becomes limited, which represents an important tumor suppressor mechanism. Cancer cells circumvent this constraint to gain an unlimited proliferative potential by acquiring a telomere maintenance mechanism (TMM).

Features of the Alternative Lengthening of Telomeres Pathway

Several characteristic features are associated with ALT activity. First, the telomere length distribution is highly heterogeneous and ranges from less than 3 kb to more than 50 kb (Fig. 1). In contrast, in human telomerase-positive cells all telomeres typically have a similar length of around 10 kb. Second, ALT-positive cells have been described to contain several classes of extrachromosomal telomeric repeats (ECTRs) in the nucleus. ECTRs comprise double- and single-stranded circular molecules, linear telomeric DNA and t-complex molecules that consist of high molecular weight DNA with highly branched structures. These DNA fragments might be products of t-loop resolution by...
The main structural components of PML-NBs are the PML and SP100 protein. They assemble into a hollow sphere with a shell thickness of 50–100 nm independent of the diameter of the whole PML-NB.22 In addition to the PML and SP100 marker proteins, an ever-growing number of factors, by now about 100, are found to associate in a transient manner with PML-NBs.32 Accordingly, PML-NBs have been implicated in a remarkably large number of nuclear activities as discussed in reference 32.

Seven different PML isoforms exist in humans with an identical N-terminus containing the so-called RBCC/TRIM motif consisting of a RING protein domain, B-boxes and a coiled-coil domain/tripartite motif. The RBCC/TRIM motif is essential for PML-NB formation as it is required for the multimerization of PML protein. The central role of PML in the formation of nuclear bodies was shown in cells lacking this protein. These cells are not only devoid of PML-NBs, but also other proteins normally residing in these compartments display an aberrant localization within the nucleus.33,34 Despite sharing an identical N-terminus, the PML isoforms show different behaviors when evaluating their dynamic exchange between a PML-NB and the surrounding nucleoplasm (Fig. 2).35 Fluorescence recovery after photobleaching (FRAP) experiments identified PML-V as the most stably bound component of PML-NBs with an average residence time of 48 min, whereas the other isoforms displayed faster exchange rates on the minute time scale. The second constitutive structural component of PML-NBs, SP100, showed a short residence time of less than 1 min in the nuclear bodies. Also other components of PML-NBs are not bound tightly. Instead, as demonstrated exemplarily in FRAP experiments for DAXX (death-associated protein 6) and BLM (Bloom syndrome protein), they can move rapidly in and out of PML-NBs (Fig. 2).35

Both PML and SP100 can be posttranslationally modified by the small ubiquitin-related modifier (SUMO) and contain SUMO interacting motifs (SIMs).36 Sumoylation is mediated by a sequence of enzymatic reactions similar to the ubiquitin pathway.
involving the E1 activating enzyme complex, the E2 conjugating enzyme UBC9 as well as E3 ligases. However, modification of a protein by SUMO does usually not trigger degradation, but allows non-covalent binding by proteins that contain SIMs. In vertebrates, three SUMO variants were shown to have a biological function. SUMO2 and SUMO3 are often not further distinguished, since they differ in only three amino acids. In contrast, human SUMO1 shares only 47% homology with SUMO2/3 and is functionally different. For instance, SUMO1 is mostly found in its conjugated form, whereas there seems to be a pool of free SUMO2/3, which is only conjugated upon cellular stress. Since PML-NBs are highly modified with all three SUMO isoforms and are enriched with sumoylated and SIM-containing proteins, they have been referred to as "sumoylation hotspots." Interestingly, the distribution of all three SUMO variants within a PML-NB is heterogeneous. While SUMO1 is mostly restricted to the surrounding shell, SUMO2/3 can be found at the shell and in the interior of the nuclear body (Fig. 2). This may reflect the differential modification of target proteins bound at different sites to the PML-NB. Notably, SUMO2/3 can also form polymeric SUMO chains, while evidence for the existence of SUMO1 chains in vivo is lacking. Thus, SUMO2/3 chains may protrude from the shell into the interior of the nuclear body (Fig. 2).

Figure 2. Dynamic structure of a PML nuclear body. A PML-NB consists of a spherical shell composed of PML and SP100 proteins, which are stabilized by non-covalent interactions of the posttranslational modification SUMO with SIM domains. The SUMO2/3 variant, which is able to form chains, is also found in the interior of the subcompartment in contrast to SUMO1, which is enriched in the PML-SP100 shell. The SUMO modifications promote binding of proteins that contain SIMs. Photobleaching experiments revealed that the PML-NB constituents are very dynamic with the exception of the PML-v isoform, which displays a high average residence time of ~50 min at NBS indicating that this isoform plays a role as a structural scaffold. PML-NB associated proteins like DAXX and BLM show a rapid turnover and can reach the interior with only a relatively small reduction in diffusive mobility. The crucial role of SUMO modifications becomes apparent during mitosis when the shell structure breaks down upon desumoylation of the PML-NB constituents. The PML protein forms unspecific aggregates by interactions of its RING domain.
scanning microscopy can detect ~4 APBs per cell with a homogeneous size distribution in 90% of unsynchronized cells in the ALT-positive U2OS osteosarcoma cell line.56 A three-dimensional high-resolution 4Pi microscopy analysis showed that the PML protein encloses the telomeric DNA by forming a shell (Fig. 3). The thickness of the PML-formed spherical layer is similar to the one measured for normal PML-NBs and independent of the total size of the APBs, i.e., small APBs appear to form with the same PML-SP100 structural scaffold as larger ones.22 Accordingly, restricting the analysis of APBs to those of large size might underestimate their number and appearance.

By definition, APBs comprise PML-NB components like PML, SP100, SUMO and telomere repeat-associated proteins like TRF1, TRF2, POT1 or RAP1.23 Additionally, they contain factors that are involved in DNA damage response and repair, such as the components of the 9-1-1 complex (hRAD9, hHUS1, hRAD1), hRAD7, the phospho-histone variant H2A.X (γH2A.X), the RecQ-like helicase BLM, heterochromatin protein HP1 or the structural maintenance of chromosome complex (SMC5/6), which includes the SUMO E3 ligase MMS21.54,57-59 Recent studies highlight the crucial role of SUMO and MMS21 for the alternative lengthening of telomeres.59,60 In addition, proteins involved in homologous recombination localize to APBs, as for example the endonuclease MUS81, replication protein A (RPA), RAD51 and RAD52, breast cancer susceptibility protein 1 (BRCA1) or the MRN complex consisting of NBS1, MRE11 (meiotic recombination 11 protein) and RAD50.23,61,62 A detailed overview of protein factors found in APBs is given in a recent review in reference 24.

Mechanisms of APB Assembly

One mechanism for the formation of APBs could be a collision between a fully assembled PML-NB and a telomere within the cell nucleus. Several studies have addressed the mobility of PML-NBs by live-cell microscopy using fluorescently labeled constructs of PML or SP100.63-66 The majority of PML-NBs display a restricted movement within a confined domain, a behavior that has also been observed with other nuclear bodies like Cajal bodies.64,67 Analyzing PML-NB movement with respect to a labeled telomere allows for a classification of nuclear bodies into those that are directly associated within the same chromatin region as the telomere and others that translocate in a more uncorrelated manner with respect to chromatin (Fig. 4A).65,68
Visualizing the dynamics of telomeres in ALT-positive cells is somewhat more challenging than those of nuclear bodies due to the presence of ECTRs, which consist of isolated telomeric sequences bound by shelterin proteins. Thus, it is difficult to exclude that telomere labels in living cells like FISH probes or GFP-tagged telomere-binding proteins reflect to some extend also complexes with ECTRs. These extra-chromosomal particles might display a higher mobility than genuine telomeres attached to a chromosome. As an alternative approach to tag telomeres, lacO arrays were introduced. 65 These lacO arrays provide high-affinity binding sites for the lac repressor LacI that can be detected as a fluorescent fusion protein in living cells.70,71 Using this system, a bimodal distribution of telomere mobility in ALT-positive U2OS cells was revealed: the main fraction of telomeres moved with lower mobility in a confined average radius of 0.36 ± 0.16 μm, whereas a fraction of 15% displayed an extended mobility with translocations in an average radius of 0.8 ± 0.1 μm in agreement with a previous report in reference 68 (Fig. 4B). Further experiments indicated an inverse correlation of telomere repeat length and telomere mobility, possibly due to the lack of interactions mediated by telomere sequence-specific binding proteins with surrounding chromatin regions. This conclusion is supported by the finding that the deletion of TRF2 results in a higher mobility. 72 Thus, short telomeres display an increased mobility in the nucleus and explore a larger nuclear volume, which could facilitate interaction with a PML-NB. Such a collisional event leading to the formation of an APB-like complex was indeed observed. 34 However, since both PML-NBs as well as telomeres are relatively immobile during interphase, collisions between them are rare events on the time scale of hours within a given cell.

A more efficient mechanism for the formation of APBs in ALT-positive cells appears to be the accumulation of soluble PML protein at a telomere, which was also observed in time-lapse microscopy experiments. 65,68 This accumulation could be mediated by the direct interaction of the telomeric repeat binding factor TRF1 with the PML-IV isoform. 73 Furthermore, several lines of evidence suggest that the assembly of PML protein at the telomere is strongly influenced by sumoylation, most likely mediated by the SUMO E3 ligase MMS21, a component of the SMC5/6 complex, that can be found in APBs. 74 (1) It has been shown that MMS21 mediates sumoylation of the shelterin components TRF1, TRF2, TIN2 and RAP1.75 Moreover, mutant variants of TRF1 and TRF2 that cannot be sumoylated do not form APBs anymore. (2) It has been reported that telomeres serve as nucleation sites for the de novo assembly of PML-NBs in both non-ALT and ALT cells. 76 This process involves the formation of a transient PML-telomere complex and subsequent detachment of the PML-NB from the chromosomal ends. PML-NR formation is accompanied by the presence of SMC5 at telomeres and sumoylation of PML is crucial for this process. It is tempting to speculate that in ALT cells a deregulated, increased sumoylation of telomeric proteins impairs the detachment of mature PML-NBs from telomeres by maintaining SUMO-SIM interactions. (3) Several SUMO-related proteins are capable of inducing de novo APBs in ALT-positive U2OS cells. 77 This was demonstrated by recruitment experiments in U2OS cells with LacO-tagged telomeres. In these experiments, GFP-tagged proteins were bound to the telomeric LacO sites by employing a fusion construct of LacI with a high-affinity GFP-binding protein domain. The propensity of inducing APB formation was evaluated by probing the presence of PML protein at that telomere. The SUMO E3 ligase MMS21, as well as SUMO itself, were found to be highly efficient in PML recruitment to the telomeres. Interestingly, a non-conjugable SUMO1 mutant was as potent in initiating APB formation as its wild-type counterpart, in contrast to a largely reduced capability of the non-conjugable mutants of SUMO2 and SUMO3. If binding to a SIM was impeded by an additional mutation of the non-conjugable SUMO1 mutant, the ability to induce APB assembly was lost. This identified the non-covalent interactions between SUMO1 and a SIM as a major driving force for the APB nucleation event. In contrast, SUMO2 and SUMO3 appear to promote APB formation mostly via their conjugation to SUMO.
A high local density of SUMO1 at the telomeres will initiate APB formation via providing a scaffold for SIM-mediated protein accumulation. An enrichment of SUMO2/3 at the telomeres via conjugation to telomere-bound proteins would be less efficient in this respect since SUMO2/3-SIM interactions appear to play only a minor role for APB nucleation. In addition, it appears likely that a sumoylation feedback mechanism exists that involves MMS21 and a potential SUMO ligase activity of PML itself. The combination of SUMO-SIM interactions and additional sumoylation creates a structural scaffold of PML and SP100 protein, to which DNA repair and recombination factors assemble subsequently.

Since multiple interactions between structural APB factors and telomeric chromatin components are involved in the assembly process, the question arises to which degree the chromatin state at the telomeres affects APB formation. Interestingly, heterochromatin appears to represent a preferential interaction surface for PML-NBs. It was shown that in fibroblasts quiescently infected with herpes simplex virus PML-NBs can accumulate viral genomes, which are associated with heterochromatin protein HP1 in their central core. Another example can be found in lymphocytes of patients suffering from the immunodeficiency, centromeric instability and facial dysmorphism (ICF) syndrome. These cells exhibit extremely large PML-containing bodies that form as a layered structure surrounding heterochromatic satellite DNA. Moreover, a direct connection between HP1 protein and APBs has been shown in RNAi-mediated knockdown experiments, which revealed the requirement of HP1α and HP1γ for APB formation. However, there is also evidence that in mice an open, euchromatic structure at telomeres promotes assembly of APB-like structures. In mouse cells, disruption of the normally heterochromatic structure of telomeres can result in the appearance of APBs and an ALT-like phenotype. Potentially, a less dense chromatin structure could facilitate recombination processes and binding of APB-related proteins at telomeres. However, one has to be cautious about comparing mouse and human cells with respect to their telomere biology. Mouse cells have extremely long telomeres and a less stringent regulation of telomerase activity, so that cell proliferation capability does not depend on telomere maintenance mechanisms.

APB Functions

It is an ongoing question of current ALT research whether APBs are—directly or indirectly—involved in the ALT mechanism, or whether they are not associated with the telomere elongation process. Two studies that relate APB formation with other proteins, which could be important for recruiting further APB components. The crucial role of SUMO-SIM interactions for formation of APBs was also apparent from the observation that various sumoylatable proteins can induce PML accumulation when highly enriched at the telomere.

The different factors that contribute to APB assembly are depicted in the scheme in Figure 5. Various PML-NB proteins can induce a nucleation event at a telomere. From the above findings on the role of sumoylation we conclude that any process that will lead to a high local density of SUMO1 at the telomeres will initiate APB formation via providing a scaffold for SIM-mediated protein accumulation.
senescence in ALT-positive cells argue in support of the latter view. It was proposed that upon induction of senescence the histone chaperone HP1 relocates to PML-NBs. In ALT cells this process could lead to the recruitment of HP1, telomeric DNA and possibly a histone methyltransferase. As a result, compaction of telomeric DNA would be promoted, which could repress recombination. As large APBs are found only in ~5% of cells, it was suggested that APBs represent a fraction of cells that have spontaneously undergone growth arrest. However, this conclusion is challenged by the finding that smaller APBs can be detected in 50–90% of proliferating ALT cells, which argues against a general association of APBs with growth arrest. Furthermore, also in non-ALT cells telomeric associations drastically increase upon induction of quiescence. Therefore, the primary result of senescence could be the clustering of telomeres that leads to an appearance of larger co-localizations of PML and telomeres.

On the other hand, several lines of evidence argue strongly for APBs having a functional role for ALT. First, the appearance of APBs is a robust marker for the identification of human tumors that utilize the ALT mechanism. Only in rare cases APB appearance and ALT are not linked as discussed in further detail below. Second, repression of the ALT mechanism in cell hybrids of ALT cells with telomerase-positive tumor cells is accompanied by the disappearance of APBs, whereas APBs assemble upon activation of ALT-mediated telomere maintenance. Third, experimental disruption of APBs by sequestration of the MRE11-RAD50-NBS1 complex away from the telomeres or knockdown experiments of components of the SMC5/6 complex results in simultaneous shortening of telomeres. These data can be rationalized by different mutually non-exclusive roles of APBs in alternative telomere elongation. APBs could either operate by driving ALT-relevant processes or by being required to avoid senescence or apoptosis. In support of the latter view it was proposed that linear ECTRs, which might result from telomeric recombination events, are sequestered by APBs. This could prevent ECTRs from being recognized as DNA double-strand breaks and from triggering cell cycle arrest. The dynamic structure of APBs and PML-NBs poses a challenge for identifying their native composition by classical purification approaches. Thus, an experimental demonstration that ECTRs are indeed accumulated in APBs within the cell is currently missing. Similar to their proposed function for sequestering ECTRs, APBs assembled at very short telomeres could prevent DDR induction by replacing the function of the missing shelterin proteins. However, disruption of APBs does not lead to a fast induction of senescence and apoptosis, which is in apparent contradiction to the prediction that they are needed to avoid growth arrest. Alternatively, APBs could actively promote telomere elongation by providing templates for replication- and recombination-based telomere lengthening or by recruiting proteins that facilitate these processes. Considering what we know about PML-NBs it appears likely that both PML-NBs and APBs provide catalytic surfaces for certain reactions that would proceed less efficiently in the absence of these nuclear subcompartments. For PML-NBs this is apparent from the multitude of enzymatic activities that are associated with them. Specific examples are the requirement of PML-NBs for phosphorylation-mediated p53 activation or the possible role of the PML protein as a SUMO E3 ligase in a sumoylation feedback cycle as proposed above.

A role of APBs as sites that provide templates for DNA recombination or replication could involve the accumulation of ECTRs as well as the promotion of telomere clustering. Artificial enlargement of APBs using a mutated Herpes virus protein ICp0 resulted in clustering of several telomeres at the surface of these bodies. Also live cell imaging experiments revealed that PML bodies dynamically associate with one and more telomeres, thereby possibly facilitating intertelomeric recombination. Due to their ability to enrich certain proteins and/or enhance their activity, APBs can promote replication- and/or homologous recombination-mediated extension of telomeres, which was shown in several studies. Artificial enlargement of APBs resulted not only in clustering of several telomeres but also filamentous telomeric bridges were observed in metaphase spreads. The latter structures suggested that intertelomeric recombination was initiated but not resolved at the enlarged PML bodies. Further evidence for telomeric extension taking place in APBs comes from the detection of non-replicative DNA synthesis in these subcompartments. Additionally, a recent study revealed the induction of telomere extension through a DNA repair mechanism by artificially accumulating PML at specific telomeres in an ALT cell line. The resulting de novo formed APBs co-localized with sites of non-replicative DNA synthesis and the DSB repair marker histone H2A.X and led to an increase of the telomere repeat length.

In summary, strong evidence exists for a role of APBs in actively promoting alternative telomere lengthening. Dissecting their function further would require knowledge of molecular details of the ALT mechanism to test which specific reaction steps are facilitated by APBs. To date, this information is missing but several models are currently investigated and are described in a number of excellent reviews.

### Triggering ALT Activity by a Sequence of Deregulation Events

The existence of PML and telomere co-localizations in ALT-positive cells was discovered more than ten years ago. Their appearance was assumed to be an exclusive feature of ALT-positive immortalized cell lines and tumors. However, PML-telomere co-localizations have recently been reported to be present also in ALT-negative cells. In order to distinguish these colocalizations from APBs, which by definition are only present in ALT-positive cells, the term telomere-associated PML bodies (TPBs) was introduced. Small TPBs (<0.9 μm in diameter) were found in several non-neoplastic cells in the absence of any TMM. The highest frequency of TPBs (median 7–15% of cells) was detected in mesenchymal tissues, from which most ALT tumors arise. Interestingly, the frequency of TPBs was increased upon induction of DNA damage. This suggests that TPBs in mortal cells...
downregulation of a counteracting desumoylation enzyme like one of the SENP proteins.\textsuperscript{59} Fusions of mortal cells with ALT-positive cells lose ALT activity, indicating that ALT requires loss of a normal function that represses ALT activity.\textsuperscript{96} This is also the case for hybrids between ALT and telomerase-positive cells.\textsuperscript{96,97} Although the mechanism that represses ALT-mediated DNA replication and recombination events at the telomeres in normal cells is still unknown, it appears reasonable to assume that the repressive function is not performed by a single factor. Thus, it seems likely that a series of changes is necessary to initiate ALT (Fig. 6).\textsuperscript{55} The above considerations imply that TPB formation might be one of these events. Yet, TPB formation alone does not seem to be sufficient to trigger ALT activity suggesting that other deregulation steps are necessary for ALT function. Likely candidates are DNA repair pathways, the telomeric chromatin state and the integrity of the telomere-bound shelterin complex. In this context p53 appears particularly interesting, since the vast majority of ALT cell lines are impaired in the p53 pathway, and there is evidence that mutations in the p53 gene are

carry out repair processes at telomeres in a mechanism similar to that in ALT-positive tumors, but that other yet unknown factors repress ALT function. Large TPBs (> 0.9 μm) have also been described in 92% of low-grade astrocytomas that lack both alternative lengthened telomeres and telomerase activity.\textsuperscript{55} As ALT is activated in higher-grade astrocytomas, the emergence of an ALT phenotype was suggested to be associated with the progression from grade 1 to grade 2/3. Although direct evidence for the progression from TPB-positive cells to ALT-positive tumors is lacking, it is tempting to speculate that the appearance of TPBs is a first step toward ALT initiation, i.e., represents a pre-ALT phenotype (Fig. 6).\textsuperscript{55} Taken together, APBs are likely to emerge due to a deregulation of a normal cellular process. A likely candidate is the sumoylation pathway since de novo formation of PML-NBs was reported to take place at telomeres in a SUMO-dependent manner in both ALT and non-ALT cells.\textsuperscript{60,74} Furthermore, SUMO enrichment at telomeres is sufficient to induce APB assembly in ALT cells.\textsuperscript{60} Increased sumoylation could occur, for example via enrichment of MMS21 at the telomeres or by inhibition or downregulation of a counteracting desumoylation enzyme like one of the SENP proteins.\textsuperscript{59} Fusions of mortal cells with ALT-positive cells loose ALT activity, indicating that ALT requires loss of a normal function that represses ALT activity.\textsuperscript{96} This is also the case for hybrids between ALT and telomerase-positive cells.\textsuperscript{96,97} Although the mechanism that represses ALT-mediated DNA replication and recombination events at the telomeres in normal cells is still unknown, it appears reasonable to assume that the repressive function is not performed by a single factor. Thus, it seems likely that a series of changes is necessary to initiate ALT (Fig. 6).\textsuperscript{55} The above considerations imply that TPB formation might be one of these events. Yet, TPB formation alone does not seem to be sufficient to trigger ALT activity suggesting that other deregulation steps are necessary for ALT function. Likely candidates are DNA repair pathways, the telomeric chromatin state and the integrity of the telomere-bound shelterin complex. In this context p53 appears particularly interesting, since the vast majority of ALT cell lines are impaired in the p53 pathway, and there is evidence that mutations in the p53 gene are
associated with ALT occurrence in glioblastoma. The p53 protein is involved in the damaged response to dysfunctional telomeres and restoring functional p53 in ALT cells leads to telomere DDR-induced cell cycle arrest and senescence. This finding suggests that activation of ALT requires loss of normal p53 function. In line with this view, it has been proposed that reconstitution of p53 inhibits DNA synthesis in ALT cells by suppression of telomeric recombination. In ALT cells the DDR checkpoint kinase ATM was found to be constitutively active and ALT-positive cell lines lacking wild-type p53 show many telomeres with a DDR. We conclude that a permanently activated DDR is present in ALT cells but without triggering growth arrest due to inactivation of p53. However, the absence of functional p53 alone is not sufficient for immortalization.

Other potential events involved in the emergence of ALT activity might be the loss of ATRX and DAXX mutations in the histone H3 variant H3.3. ATRX and DAXX are known to interact with each other. Among other functions they are required for the non-replicative incorporation of H3.3 at telomeres. Moreover, they were suggested to facilitate heterochromatin assembly at repetitive G-rich regions, for instance at telomeres. Interestingly, ALT activity was found to be highly correlated with the simultaneous occurrence of mutations in the TP53, ATRX and H3F3A genes (encoding for p53, ATRX and H3.3) in a recent genome analysis of pediatric glioblastomas. It was shown that incorporation of mutant H3.3 results in changes in the expression profiles, which could facilitate ALT appearance. Furthermore, a model has been proposed, in which loss of ATRX-DAXX function inhibits the formation of heterochromatic features at the telomeres, possibly as a result of reduced incorporation of H3.3. These changes of the telomeric chromatin state could lead to increased homologous recombination associated with ALT activity. In addition, ATRX seems to be responsible for repression of the telomeric non-coding transcript TERRA, which displays elevated levels in some ALT cell lines and tumors. Disturbing the shelterin-mediated protection of telomeres might be another factor that favors ALT initiation. The shelterin complex binds telomeric DNA and participates in t-loop formation, which represses DDR and telomeric recombination. It has been demonstrated that in ALT-positive cells DDR can be partly suppressed by TRF2 overexpression. Furthermore, some ALT-positive cell lines have low ratios of TRF2 to telomeric DNA, i.e., a relative deficiency of TRF2 at the telomeres. The resulting reduced shelterin protection might favor recombination events at the telomeres. Finally, a deregulated sumoylation pathway might also decrease telomere protection. As discussed above, impaired sumoylation of the shelterin components TRF1 and TRF2 was shown to inhibit APB formation. As one putative sumoylation site of TRF2 is located in the TRFH domain, which mediates TRF2-dimerization, sumoylation of shelterin components could lead to their dissociation from telomeres. This supports the conclusion that deregulation of the sumoylation-desumoylation equilibrium predisposes for the emergence of an ALT phenotype.

Different Alternative Telomere Lengthening Mechanisms

As discussed above, different combinations of deregulation events are presumably able to trigger ALT activity according to the scheme depicted in Figure 6. Several findings support the hypothesis that more than one mechanism for telomerase-independent telomere elongation exists. There is the canonical ALT pathway displaying its characteristic features, namely heterogeneous telomere length (HTL), ECTRs and T-SCEs. Within this pathway two mutually non-exclusive mechanisms for telomere elongation, the unequal T-SCE and the homologous recombination-dependent DNA synthesis, have been proposed. Furthermore, it has been demonstrated that there are different templates for recombination-mediated DNA replication of telomeres in ALT cells including the same telomere via t-loop formation, the telomere of a sister chromatid or the telomere of another chromosome. In addition, linear or circular ECTRs could serve as templates. The variety of possible templates can be related to different mechanisms for telomere elongation such as rolling circle amplification for circular forms of ECTRs or break-induced replication for recombination between telomeres. These recombination/repair mechanisms might operate in parallel. Thus, already within the canonical pathway there are several possible molecular routes for telomere elongation.

In addition to the canonical ALT mechanism other telomerase-independent telomere maintenance mechanisms exist. In a few cases it was demonstrated that elongation of telomeres could occur in telomerase-negative cells in the absence of one or more of the canonical ALT features mentioned above. For example, one cell line was reported to lack APBs but featured all other canonical ALT characteristics. Remarkably, though lacking APBs, this telomerase-negative SV40-immortalized fibroblast cell line still showed nuclear aggregates of APB components at telomeres. These aggregates contained the SV40 large T antigen possibly formed via binding to the SV40 origin of replication sequences integrated into telomeres of this cell line. Due to its interaction with many proteins, the SV40 large T antigen appears to be able to replace the function of sumylated PML in this case. Thus, although composition and structure might differ, nuclear domains comprising telomeric DNA and proteins involved in DNA processing seem to be important for telomerase-independent telomere maintenance. Moreover, the presence of ECTRs cannot always be correlated with ALT activity. Some ALT cell lines lack ECTRs, and low levels of ECTRs were detected in telomerase-positive and mortal cells. ECTRs were also reported to accumulate in a telomerase-positive cancer cell line upon upregulation of telomerase activity where they might result from trimming of overlengthened telomeres, most likely by resolution of the t-loop. Regarding the different classes of ECTRs, the so-called C-circles appear to be the most robust marker for ALT activity. Another example for a “non-canonical” ALT pathway is an immortalized ALT-derived human cell line that maintains its telomeres in a telomerase-independent manner in the absence of several canonical ALT features, namely APBs, heterogeneous telomere length and ECTRs. However, a T-SCE
phenotype was observed and also C-circles were detected. These reports indicate that more than one telomerase-negative TMM exist, which is further supported by the analysis of tumor samples and a cell line that lack both detectable telomerase activity and characteristics of the ALT pathway.

In summary, the fact that APBs and other ALT markers are not observed in some telomerase-negative tumors and cell lines does not necessarily argue against their functional role in the canonical ALT pathway. Rather it suggests that different alternative telomere maintenance strategies exist. It is crucial to decipher the precise pathways and hallmarks of these TMMs. Since canonical ALT features seem not to be universal for ALT function, a systematic reassessment of known ALT markers (and possible other TMM features) in terms of their simultaneous presence would provide valuable information in this respect. This is especially relevant for the identification of the specific TMM that is active in a particular cell line or tumor, as well as for the design of anti-cancer therapies targeting telomere maintenance.

Identification and Targeting of APBs in Tumors

In addition to being a marker for ALT activity, APBs have a yet hardly exploited potential for being used as a prognostic tumor marker. This has been demonstrated for liposarcoma and neuroblastomas where the presence of APBs is associated with poor survival. Several approaches have been developed to inhibit telomerase drugs should have reduced side effects on healthy somatic cells. Of a TMM is specific to cancer and stem cells. Accordingly, these approaches for preventing tumor growth since the shortening of the chromosomal ends during further replication rounds might finally result in induction of senescence. Moreover, the presence of a TMM is specific to cancer and stem cells. Accordingly, these drugs should have reduced side effects on healthy somatic cells. Several approaches have been developed to inhibit telomerase activity in order to treat telomerase-positive tumors. Some of them are currently tested in phase III clinical studies. However, therapies that employ telomerase inhibitors might lead to a selective emergence of an ALT-positive cancer cell population, even if the tumor initially was ALT-negative. Furthermore, there is evidence that both telomerase activity and ALT can coexist in human cell lines. Assuming that this also holds true for tumors, anticancer drugs targeted against telomerase will be hardly effective in these cases since ALT activity will still provide a telomere maintenance pathway. As discussed above, several lines of evidence suggest that disruption of APBs would reduce the proliferation potential of tumor cells that use the canonical ALT mechanism. It is predicted that inhibiting a factor that is able to initiate APB formation would result in telomere shortening and finally induction of senescence. One promising candidate would be the SUMO E3 ligase MMS21 that was shown to be an efficient APB-inducing factor. The siRNA-mediated knockdown of MMS21 disrupts APBs and induces senescence in ALT—but not in telomerase-positive cells. Thus, developing therapeutic strategies that target MMS21 or other proteins essential for APB formation and/or function could represent a currently not exploited option for the specific treatment of ALT-positive tumors.

Conclusion

Several lines of evidence indicate that APBs assemble in a SUMO-SIM-interaction-dependent manner. They represent important functional intermediates in the ALT pathway and can induce telomere elongation in the absence of active telomerase (Fig. 5). In addition to APB formation, several deregulation events that influence cellular DNA damage response, telomeric chromatin and possibly other factors are required in order to activate the ALT pathway for extending the chromosomal ends (Fig. 6). Depending on the combination of deregulating events occurring in a given cell, different ALT-phenotypes are observed. The prevalent canonical ALT pathway involves APBs, ECTRs, T-SCEs and a heterogeneous telomere length distribution. In contrast, the less frequently observed non-canonical ALT pathways lack the APB-inducing factor. The siRNA-mediated date would be the SUMO E3 ligase MMS21 that was shown to be an efficient APB-inducing factor. The siRNA-mediated knockdown of MMS21 disrupts APBs and induces senescence in ALT—but not in telomerase-positive cells. Thus, developing therapeutic strategies that target MMS21 or other proteins essential for APB formation and/or function could represent a currently not exploited option for the specific treatment of ALT-positive tumors.

References

1. Makarov VL, Hirose Y, Langmore JP. Long G tails in cells of human fibroblasts. Nature Cell Biol 1999; 1:105-10; PMID:10454580; http://dx.doi.org/10.1016/S1357-2725(99)01677-2.
2. Griffith JD, Concannon P, Rosselli S, Birdoi RM, Benz JR, Mele H, et al. Manifestation telomeres in a large duplica loop. Cell 1999; 97:503-14; PMID:10503064; http://dx.doi.org/10.1016/S0092-8674(00)81207-8.
3. de Lange T, Howell brents transposable mam- malian telomeres. Annu Rev Genet 2000; 42:23-41; PMID:10809844; At http://dx.doi.org/10.1146/annurev.genet.41.110306.130350.
4. de Lange T, Howel brents the protein complex that regulates and elongates human telomeres. Genes Dev 2005; 19:239-50; PMID:16036375; http://dx.doi.org/10.1101/gad.134655.
5. Harley CR, Fuchs AF, Greider CW. Telomeres shorten during aging of human fibroblasts. Nature 1990; 345:586-90; PMID:2354270; http://dx.doi.org/10.1038/345586a0.
6. Filleri E, Fugaki E, Bauer PM, Cle-Farrace L, Togari H, Ruts ZR, et al. DNA-dam- age checkpoint response in telomere-initiated senes- cease. Nature 2003; 426:229-18; PMID:14590306; http://dx.doi.org/10.1038/nature02118.
7. Filleri E, Fugaki E, Bauer PM, Cle-Farrace L, Togari H, Ruts ZR, et al. DNA-dam- age checkpoint response in telomere-initiated senes- cease. Nature 2003; 426:229-18; PMID:14590306; http://dx.doi.org/10.1038/nature02118.
8. Collado M, Blasco MA, Soriano M. Cellular senes- ce in cancer and aging. Cell 2007; 130:223-33; PMID:17625938; http://doi.org/10.1016/j.cell.2007.07.038.
9. Harr PW, Rocklin S. A survey of telomere activ- ity in human cancer. Eur J Cancer 1997; 33:708-16; PMID:92482118; http://dx.doi.org/10.1016/S0959-8049(97)00002-9.
10. Kim NW, Piatyszek MA, Prowse KR, Harley CB, Weinhold K, Peiper SC, et al. Prevalence of the age checkpoint response in telomere-initiated senesce- nce in human cancer. Exp Cell Res 2011; 179:1608-13; PMID:21888887; http://dx.doi.org/10.1016/j.feb- cel.2011.06.089.
11. Hochedz CM, Subbarama SS, Hoover MG, Gajewski MG, Montgomery GA, Gajewski MG, et al. Prevalence of the age checkpoint response in telomere-initiated senesce- nce in human cancer. Exp Cell Res 2011; 179:1608-13; PMID:21888887; http://dx.doi.org/10.1016/j.feb- cel.2011.06.089.
12. Kim NW, Piatyszek MA, Prowse KR, Harley CB, Weinhold K, Peiper SC, et al. Prevalence of the age checkpoint response in telomere-initiated senesce- nce in human cancer. Exp Cell Res 2011; 179:1608-13; PMID:21888887; http://dx.doi.org/10.1016/j.feb- cel.2011.06.089.
13. Hochedz CM, Subbarama SS, Hoover MG, Gajewski MG, Montgomery GA, Gajewski MG, et al. Prevalence of the age checkpoint response in telomere-initiated senesce- nce in human cancer. Exp Cell Res 2011; 179:1608-13; PMID:21888887; http://dx.doi.org/10.1016/j.feb- cel.2011.06.089.
15. Ceasar AJ, Griffith JD. Telomeric DNA in ALT cells is characterized by telomeric foci and branched DNA. J Biol Chem 2006; 281:24944-51. PMID:16694253.

16. Ogino H, Nakajima K, Sasaki M, Takahashi E, Hagiwara H, Nakamura S. Telomere DNA from chromosomes in immortal human cells lacking telomerase activity. FEBS Lett 1999; 468:223-7. PMID:9767517.

17. Tokutake Y, Matsumoto T, Watanabe T, Maeda S, Saito I. Telomeric DNA in a human alternative lengthening of telomeres cell line. Cell Tissue Bank 2007; 8:139-43. PMID:17843035.

18. Cesar AJ, Reddel RR. Alternative lengthening of telomeres-associated protein 73 is upregulated in the absence of telomerase activity. Exp Cell Res 2005; 307:76-85. PMID:15718957.

19. Bacher S, Bähler J, Tschupp W, Westermann A, Soubeyran P, Dunn C, Peddi-Kalluri RS. PALB2: an essential component of mammalian telomeres. J Cell Biol 2009; 187:691-9. PMID:19981222.

20. Borchers OE, Zou Y, Walker WJ, Wright WE, Shay JW. Alternative lengthening of telomeres activity in human tumor cells. Cancer Res 2004; 64:2324-7. PMID:15364768.

21. Guarente L, Johnson FB. A novel telomere structure in telomerase-negative immortalized human cells contains a novel type of promyelocytic leukemia body. Cancer Res 1999; 59:4175-9. PMID:10485449.

22. Bacchetti S. A human cell line that maintains telomeres in the absence of telomerase and of key markers of ALT. J Cell Sci 2002; 115:3963-74. PMID:12494988.

23. Qiu KY, Ciminia AE, Ender RA, Berkel H, Ender RA, et al. Telomeric DNA is located in a novel nuclear structure when modified by SUMO-1. J Biol Chem 1999; 274:1223-34. PMID:9925743.

24. Zhang S, Mihori S, Breeden E, Breeden MD, Dunn C, Peddi-Kalluri RS. Dnajc5 is required for normal telomere function. J Cell Sci 2007; 120:1748-53. PMID:17773464.

25. Wickham-Peers S, Lanken T, Nguyen D, Gerner N, Hollstein T, Schwinn G, et al. Dynamics of chromosome association with PML nuclear bodies. J Cell Sci 2008; 121:3735-43. PMID:18664406.

26. Seller M, Hocke M, Behrens M, Hocke CM. SUMOylation dynamics. Int J Biol Sci 2010; 6:51-67. PMID:21095916.

27. Firtel RA, Fuentes VA, Ponnambalam K, Jesudason KS, et al. SUMOylation of the nuclear dot-associated proteins Sp100 and Sp84. Mol Cell Proteomics 2008; 7:1132-45. PMID:18285249.

28. Firtel RA, Fuentes VA, Ponnambalam K, Jesudason KS, et al. SUMOylation of the nuclear dot-associated proteins Sp100 and Sp84. Mol Cell Proteomics 2008; 7:1132-45. PMID:18285249.

29. Yeager TR, Robinson RA, et al. A robust assay for nuclear organogenesis in vivo strategy. Mol Cell Proteomics 2008; 7:132-45. PMID:18285249.

30. Zhang M, Tan X, Wu Z, Liu J, Roques P, et al. Telomeric DNA is located in a novel nuclear structure when modified by SUMO-1. J Biol Chem 1999; 274:1223-34. PMID:9925743.

31. Zhao J, Sadrzadeh T, Gifford-Garner J, Wiles A, Tan X, et al. SUMOylation dynamics. Int J Biol Sci 2010; 6:51-67. PMID:21095916.

32. Sterneck C, Jensen K, Will H. Evidence for covalent modification of the nuclear DNA-associated protein PML and Sp100 by SUMO-1. J Biol Chem 2007; 282:38459-68. PMID:17931438.

33. Shee TH, Lee HK, Scaglia FP, Yong TM, Peddi-Kalluri R. Telomere maintenance in telomerase-negative human cancer cells. J Cell Biol 2006; 173:455-62. PMID:16435666.

34. Dupuis E, Sorger PK, Derdier JM, Lankowitz-Bouhni L, Van Kooten K, et al. SUMO-1-modification of the acute promyelocytic leukemia protein PML implicates for nuclear localization. J Cell Sci 1999; 112:381-95. PMID:10193291.

35. Sterneck C, Jensen K, Will H. Evidence for covalent modification of the nuclear DNA-associated protein PML and Sp100 by SUMO-1. J Biol Chem 2007; 282:38459-68. PMID:17931438.

36. Sterneck C, Jensen K, Will H. Evidence for covalent modification of the nuclear DNA-associated protein PML and Sp100 by SUMO-1. J Biol Chem 2007; 282:38459-68. PMID:17931438.
274 Nucleus Volume 3 Issue 3

85. Sturzaker DR, Bradshaw PS, Li X, Tuan R, Huang S, Damer P, et al. The human syndrome RBM Inc/anti-TRAP-6 forms a complex with TRAP-6 and promotes telomere maintenance. Nucleus 2010; 1:148-59; PMID:21011980; http://dx.doi.org/10.4139/Nuc.2010.5.

86. Chen NH, Kajimura H, Pansini A, Kondo M, et al. Telomere protection by tandem repeats promotes telomere lengthening in ALT cancer cells through SUMOylation of telomeric proteins and is highly cell cycle dependent. Oncogene 2010; 29:1715-24; PMID:20087944; http://dx.doi.org/10.1038/onc.2009.528.

87. Costa A, Daidone MG, Dapri L, Villa R, Cantù S, Zanetti G, et al. Telomere length changes during late oocyte maturation are controlled by meiotic recombination and may be increased by increasing the dosage of telomerase. Nat Commun 2011; 2:256; PMID:21983621; http://dx.doi.org/10.1038/ncomms1263.

88. Nagle RG, Valente AJ, Anderson WS, McMahon DH, Thomson Z, Pintar J, et al. Telomere association in the telomere-negative cell line is sensitive to starvation-induced transcriptional repression. J Cell Biol 2011; 193:777-80; PMID:21569693.

89. Carea MF, Diulca MG, Dupuis L, Villa R, Carati S, Pintar J, et al. Telomere maintenance mechanisms in frozen-thawed human dermal fibroblasts and skin fibroblasts from patients with trichothiodystrophy and dyskeratosis congenita. Cancer Res 2006; 66:9580-8; PMID:16822773; http://dx.doi.org/10.1158/0008-5472.CAN-06-2473.

90. Pomprapa K, Colgin LM, Neumann AA, Sugar TR, Reddel RR. Constitutive alternative lengthening of telomeres is required for the formation of HIPK domains. Cancer Res 2008; 68:3759-70; PMID:18336084; http://dx.doi.org/10.1158/0008-5472.CAN-07-4798.

91. Wong MQ, Zhang ZF, Horns J, Neumann AA, Chang AC, Reddel RR. Suppression of alternative lengthening of telomeres by Sp100-mediated sequestration of BLM. Proc Natl Acad Sci USA 2009; 106:5204-9; PMID:19296678; http://dx.doi.org/10.1073/pnas.0811387106.

92. Hancock R. Functional organization of the mammalian assembly of compartments by macromolecular complexes and the nuclear matrix model. Biochim Biophys Acta 2004; 1677:9-20; PMID:14791703; http://dx.doi.org/10.1016/j.bbamcr.2008.07.022.

93. Zhan H, Li H, Luo L. Nuclear body dynamics of PML bodies in mammalian cells. Cancer Lett 2009; 279:11-7; PMID:19136680; http://dx.doi.org/10.1016/j.canlet.2009.03.010.

94. Moore J, Fodde R, Muth S, Vennegoor C, Brouwer AK, Vertegaal R, et al. Telomere recombination is required for the formation of HIPK domains. Cancer Res 2003; 63:2149-55; PMID:12778248.

95. Chou WC, Kappel C, Brandau J, Ehl S, Speichert DL. Live-cell dynamics of protein-interacting telomeric nuclear bodies: entry into S phase and exit from mitosis. Mol Cell Biol 2008; 29:154-62; PMID:19648407; http://dx.doi.org/10.1128/MCB.00039-08.

96. Giorgi SM, Wachsmuth M, Görlach SM, Wachsmuth M, Ittrich C, Bacher CP, et al. Metabolic-energy-dependent movement of PML bodies within the mammalian cell nucleolus. Oncogene 2009; 28:707-16; PMID:19261725; http://dx.doi.org/10.1038/onc.2008.309.

97. Giorgi SM, Wachsmuth M, Görlach SM, Wachsmuth M, Ittrich C, Bacher CP, et al. Telomere length changes during late oocyte maturation are controlled by meiotic recombination and may be increased by increasing the dosage of telomerase. Nat Commun 2011; 2:256; PMID:21983621; http://dx.doi.org/10.1038/ncomms1263.

98. Costea A, Daidone MG, Dapri L, Villa R, Cantù S, Zanetti G, et al. Telomere length changes during late oocyte maturation are controlled by meiotic recombination and may be increased by increasing the dosage of telomerase. Nat Commun 2011; 2:256; PMID:21983621; http://dx.doi.org/10.1038/ncomms1263.

99. Stagno D’Alcontres M, Mendez-Bermudez A, Foxon J, Williams J, et al. Telomere lengthening of telomeres (ALT) associated promyelocytic leukemia nuclear bodies requires Nijmegen Breakage Syndrome 1. Cancer Res 2011; 71:4307-18; PMID:22045732; http://dx.doi.org/10.1158/0008-5472.CAN-10-2581.

100. Hancock R. Functional organization of the mammalian assembly of compartments by macromolecular complexes and the nuclear matrix model. Biochim Biophys Acta 2004; 1677:9-20; PMID:14791703; http://dx.doi.org/10.1016/j.bbamcr.2008.07.022.
110. Goldberg AD, Banaszynski LA, Noh KM, Lewis PW, Allis CD. HIRA and Daxx constitute transcriptional repression complexes at telomeres and cooperate with ATRX in replication-independent telomere maintenance. Mol Cell 2004; 13:576-77. PMID:15319556.

111. Ng LL, Cowper SE, Piktak HT, Rood GR, Stern CM. Telomere activity is associated with an increase in DNA methylation at the proximal subtelomere and a reduction in telomere transcription. Nucleic Acids Res 2009; 37:1352-9. PMID:1914228; http://dx.doi.org/10.1093/nar/gkp500.

112. Samp J, Paandar S, Seng C, Penrose M, Marcel C, Holmén K. Expression of Daxx in Tumors of the Anterior Mediastinum WHO Grade 2 to 4: TERRA Level Correlates with Telomere Length, Telomerase Activity and Advanced Clinical Grade. Transl Oncol 2012; 5:56-65. PMID:22344617.

113. Wang RC, Stroemmea ES, Ait-Louhichi H. Echinobothrida echinoderm genome targeted silencing of human telomeres. Cell. 2004; 119:355-68. PMID:15507287; http://dx.doi.org/10.1016/j.cell.2004.10.011.

114. Fairall L, Chapman L, Moss H, de Lange T, Rhodes MC. The ATRX syndrome protein forms a transcriptional repression complex at telomeres and survival in patients with glioblastoma multiforme. Lancet 2003; 361:836-8. PMID:12642053; http://dx.doi.org/10.1016/S0140-6736(03)14143-4.

115. Muntoni A, Neumann AA, Hills M, Reddel RR. Telomere elongation involves intermolecular DNA replication in cells utilizing alternative lengthening of telomeres. Hum Mol Genet 2009; 18:1017-27. PMID:19091776; http://dx.doi.org/10.1093/hmg/ddp140.

116. Dunham MA, Neumann AA, Fasching CL, Reddel RR. Telomere maintenance by recombination in human cancer cell lines. Nucleus. 2008; 2:79-89. PMID:18919889; http://dx.doi.org/10.1080/21541231.2011.560743.

117. Rudly C. Telomere Inhibition: Approaches and Clinical Trials. Curr Opin Pharmacol. 2012; 12:673-7. PMID:22648681; http://dx.doi.org/10.1016/j.coph.2012.04.005.

118. Hsu M, Lam L, Hoare SF, Daidone MG, Zaffaroni N, Hiyama K. Telomere biology in neuroblastoma: the ALT phenotype and poor prognosis in liposarcoma. Br J Cancer 2012; 106:1876-9. PMID:22461847; http://dx.doi.org/10.1038/bjc.2012.298.

119. Venturini L, Mari R, Gontis A, DiDio M, Zaffaroni N. Prognostic significance of ALT-associated markers in patients with pulmonary adenocarcinoma. BMC Cancer 2010; 10:254. PMID:20525264; http://dx.doi.org/10.1186/1471-2407-10-254.

120. Barchner A, Sasgary S, Pirker C, Rodgarkia C, Mikula VT, Lamberg A, et al. Clinical Grade. Transl Oncol 2012; 5:56-65. PMID:22344617.